Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
7 participants
INTERVENTIONAL
2007-09-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome
NCT01845428
Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)
NCT01870804
Study of Atorvastatin Dose Dependent Reduction of Proteinuria
NCT00768638
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
NCT00380939
Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients
NCT02561845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These data suggest that statins have the potential to inhibit albumin uptake by the human proximal nephron as a result of inhibition of HMG-CoA reductase in the proximal tubule cells. A reduced prenylation of some proteins critically involved in endocytosis has been put forward as the underlying mechanism.
Knowing these data it has been suggested that the occurrence of proteinuria in some patients treated with high statin doses is the result of a reduced tubular reabsorption/endocytosis of normally filtered proteins. To further explore the clinical relevance of such a mechanism, the composition of the urinary proteome under statin treatment will be investigated in normal healthy volunteers by two-dimensional gel electrophoresis based proteomics analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosuvastatin-Crestor
Pravastatin-Pravasine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smoker
* Proteinuria: \< 60 mg/24 hours
* Dipstick negative hematuria
* Bloodpressure: \< 135 mm systolic, \< 85 mm dyastolic
* Waist circumference: \< 94 cm
Exclusion Criteria
* Known history of diabetes or fasting glucose level: \< 110 mg/dl
* Anti-hypertensive medication
* Life-expectancy \< 1 year
* Pharmacological treatment with inotropes
* Acute or chronic inflammatory process, use if anti-inflammatory drugs or immunosuppression
* Clinically active malignant disease
* Administration of any investigational drug within 30 days preceding study start and during the study
* Known intolerance to rosuvastatin or other statins
* Acute or chronic liver disease or ALAT\>2.0 x upper limit of normal (ULN) at enrolment visit.
* Chronic muscle disease such as dermatomyositis or polymyositis or unexplained creatinine kinase (CK) above 3 x ULN at enrolment.
* Uncontrolled hypothyroidism as indicated by a thyroid stimulating hormone (TSH) \> 2 x ULN at enrolment.
* Renal insufficiency: creatinine \> 2.0mg/dl
* Known or suspect alcohol or drug abuse.
25 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universiteit Antwerpen
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick C D'Haese, Prof
Role: STUDY_DIRECTOR
Universiteit Antwerpen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Antwerp
Antwerp, Antwerp, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STAT-AZ-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.